0.823
0.03 (3.60%)
| Penutupan Terdahulu | 0.794 |
| Buka | 0.821 |
| Jumlah Dagangan | 7,485,481 |
| Purata Dagangan (3B) | 6,413,333 |
| Modal Pasaran | 179,411,136 |
| Harga / Pendapatan (P/E Ke hadapan) | 23.81 |
| Harga / Jualan (P/S) | 71.34 |
| Harga / Buku (P/B) | 57.77 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 27 Mar 2026 |
| Margin Operasi (TTM) | -4,484.33% |
| EPS Cair (TTM) | -0.690 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 228.93% |
| Nisbah Semasa (MRQ) | 3.68 |
| Aliran Tunai Operasi (OCF TTM) | -99.38 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -67.40 M |
| Pulangan Atas Aset (ROA TTM) | -42.82% |
| Pulangan Atas Ekuiti (ROE TTM) | -249.75% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Humacyte, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | -2.5 |
| Purata | -0.13 |
|
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 20.16% |
| % Dimiliki oleh Institusi | 40.20% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 25.00 (D. Boral Capital, 2,937.67%) | Beli |
| Median | 10.00 (1,115.07%) | |
| Rendah | 6.00 (BTIG, 629.04%) | Beli |
| Purata | 13.67 (1,561.00%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 1.12 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| D. Boral Capital | 19 Feb 2026 | 25.00 (2,937.67%) | Beli | 1.15 |
| 09 Feb 2026 | 25.00 (2,937.67%) | Beli | 1.22 | |
| BTIG | 09 Feb 2026 | 6.00 (629.04%) | Beli | 1.22 |
| Benchmark | 21 Jan 2026 | 10.00 (1,115.07%) | Beli | 0.980 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 08 Jan 2026 | Pengumuman | Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications |
| 05 Jan 2026 | Pengumuman | Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |